Stem Cell Innovations, Inc. has a business relating to the use of the Company's C3A human liver cell line in the field of drug discovery and toxicology testing. The Company has not yet developed any substantial market for its primary products. Stem Cell Innovations' principal revenues have been contract research and testing and consulting services for other companies, which have historically been minimal. Stem Cell Innovations intends to develop its C3A human liver cell line for the production of human serum proteins, including the clotting factors, Factor VIII and Factor IX, used by hemophiliacs to allow their blood to clot. It also intends to broaden the application of its expertise into the area of pluripotent cell biology.